DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Relafen (Nabumetone) - Indications and Dosage

 
 



INDICATIONS AND USAGE

Carefully consider the potential benefits and risks of RELAFEN and other treatment options before deciding to use RELAFEN. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).

RELAFEN is indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis.

DOSAGE AND ADMINISTRATION

Carefully consider the potential benefits and risks of RELAFEN and other treatment options before deciding to use RELAFEN. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).

After observing the response to initial therapy with RELAFEN, the dose and frequency should be adjusted to suit an individual patient’s needs.

Osteoarthritis and Rheumatoid Arthritis

The recommended starting dose is 1,000 mg taken as a single dose with or without food. Some patients may obtain more symptomatic relief from 1,500 mg to 2,000 mg per day. RELAFEN can be given in either a single or twice-daily dose. Dosages greater than 2,000 mg per day have not been studied. The lowest effective dose should be used for chronic treatment (see WARNINGS, Renal Effects). Patients weighing under 50 kg may be less likely to require dosages beyond 1,000 mg; therefore, after observing the response to initial therapy, the dose should be adjusted to meet individual patients’ requirements.

HOW SUPPLIED

Tablets

Oval-shaped, film-coated: 500 mg−white, imprinted with the product name RELAFEN and 500, in bottles of 100. 750 mg−beige, imprinted with the product name RELAFEN and 750, in bottles of 100.

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) in well-closed container; dispense in light-resistant container.

500 mg 100’s: NDC 0029-4851-20

750 mg 100’s: NDC 0029-4852-20

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012